NCT01234129View on ClinicalTrials.gov

Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma

CompletedOBSERVATIONAL

Enrollment

320

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Multiple Myeloma

Interventions

DRUG

zoledronic acid

zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years

Trial Locations (1)

06725

Tertiary reference oncology center, Mexico City

All Listed Sponsors

lead

Instituto Mexicano del Seguro Social

OTHER_GOV

NCT01234129 - Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter